Astrotech Reports Third Quarter of Fiscal Year 2026 Financial Results
Rhea-AI Summary
Astrotech (Nasdaq: ASTC) reported results for the third quarter of fiscal 2026, ended March 31, 2026. Research and development expense was $554 thousand, described as a 28% decline as the company transitions from development to saleable EN-SCAN Handheld GC and 1st Detect TRACER 1000 products.
Through March 31, 2026, the TRACER 1000 trace detection system had been deployed in about 37 locations across 16 countries in the United States, Europe and Asia, supporting commercialization efforts and customer engagement in industrial, safety and trace detection markets.
Positive
- R&D expense reported at $554 thousand, a stated 28% decline
- Transition from development stage to saleable EN-SCAN and TRACER 1000 products
- TRACER 1000 deployed in approximately 37 locations across 16 countries
Negative
- None.
News Market Reaction – ASTC
In the May 13 session, ASTC declined 0.37%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 13 | Q2 FY2026 earnings | Positive | -3.5% | R&D expense reduction and shift toward saleable products with leadership changes. |
| Nov 13 | Q1 FY2026 earnings | Positive | +0.0% | Revenue growth, stronger cash of $13.9M and expanding TRACER 1000 footprint. |
| Sep 25 | FY2025 results | Neutral | +2.0% | Full-year revenue of $1.0M with 45.3% margin and solid cash balance. |
| May 13 | Q3 FY2025 earnings | Positive | +0.8% | Q3 FY2025 revenue jump to $534,000 and multiple DHS-related contracts. |
| Feb 14 | Q2 FY2025 earnings | Positive | +2.5% | Q2 FY2025 revenue of $295K and strong $24.7M cash and investments. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have usually seen flat-to-positive moves, with one notable negative divergence.
Across prior earnings releases, Astrotech highlighted growing TRACER 1000 deployments (from 15 to 34 locations across 16 countries), revenue growth in Q3 FY2025 to $534,000, and strong cash positions up to $24.7 million. Fiscal 2025 results showed revenue of $1.0 million and a 45.3% gross margin. These updates emphasized commercialization and contract wins. Today’s Q3 FY2026 update continues that narrative with lower R&D spend and incremental deployment growth, reinforcing the shift from development to sales.
Key Terms
mass spectrometry medical
trace detection technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2026, which ended March 31, 2026.
Financial Highlights & Recent Developments
- Research and development expense was
$554 thousand , a decline of28% from the third quarter of fiscal year 2026 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect TRACER 1000 product lines. - Through March 31, 2026, the Company has deployed the TRACER 1000 trace detection system in approximately 37 locations in 16 countries across the United States, Europe and Asia.
“During the third quarter of fiscal year 2026, we remained focused on disciplined execution, achieving targeted cost-efficiency initiatives while continuing to invest selectively in the highest-return areas of the business. As a result, we are better positioned to operate efficiently in a dynamic macro environment. At the same time, our sales team is advancing a healthy sales pipeline supported by strong lead generation and ongoing customer engagement across key markets. Our deployments to date support these efforts with real-world demonstration of our solution capabilities and compelling data affirming the unique benefits of mass spectrometry technology in industrial, safety and trace detection applications. Looking ahead, we will continue to balance rigorous expense control with strategic investments to help convert pipeline opportunities into revenue growth”, said Thomas B. Pickens, III, Astrotech’s Chairman and Chief Executive Officer.
About Astrotech Corporation
Astrotech Corporation (Nasdaq: ASTC) is an instrumentation company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech’s core technology to serve specialized markets:
- 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening.
- AgLAB designs process analyzers tailored to the processing of agriculture products.
- Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing.
- EN-SCAN, Inc. delivers portable, ruggedized environmental GC-MS for on-site testing of air, water and soil.
Astrotech is headquartered in Austin, Texas. For more information, visit www.astrotechcorp.com
Forward-Looking Statements
This press release contains “forward-looking statements” that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Company Contact:
Scott Bartley
Interim Chief Financial Officer, Astrotech Corporation
(512) 485-9530
Investor Contact:
Matt Kreps
Managing Director, Darrow Associates
(214) 597-8200 mkreps@darrowir.com
Financial tables follow
| ASTROTECH CORPORATION AND SUBSIDIARIES Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share data) (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31, | March 31, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | 343 | $ | 534 | $ | 787 | $ | 829 | ||||||||
| Cost of revenue | 276 | 297 | 525 | 428 | ||||||||||||
| Gross profit | 67 | 237 | 262 | 401 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 2,085 | 2,115 | 5,941 | 5,842 | ||||||||||||
| Research and development | 1,435 | 1,989 | 5,211 | 6,375 | ||||||||||||
| Total operating expenses | 3,520 | 4,104 | 11,152 | 12,217 | ||||||||||||
| Loss from operations | (3,453 | ) | (3,867 | ) | (10,890 | ) | (11,816 | ) | ||||||||
| Other income and expense, net | (315 | ) | 234 | (271 | ) | 896 | ||||||||||
| Loss from operations before income taxes | (3,768 | ) | (3,633 | ) | (11,161 | ) | (10,920 | ) | ||||||||
| Net loss | $ | (3,768 | ) | $ | (3,633 | ) | $ | (11,161 | ) | $ | (10,920 | ) | ||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic and diluted | 1,677 | 1,665 | 1,676 | 1,663 | ||||||||||||
| Basic and diluted net loss per common share: | ||||||||||||||||
| Net loss per common share | $ | (2.25 | ) | $ | (2.18 | ) | $ | (6.66 | ) | $ | (6.57 | ) | ||||
| Other comprehensive loss, net of tax: | ||||||||||||||||
| Net loss | $ | (3,768 | ) | $ | (3,633 | ) | $ | (11,161 | ) | $ | (10,920 | ) | ||||
| Available-for-sale securities: | ||||||||||||||||
| Net unrealized gain (loss) | 159 | 139 | 476 | 236 | ||||||||||||
| Total comprehensive loss | $ | (3,609 | ) | $ | (3,494 | ) | $ | (10,685 | ) | $ | (10,684 | ) | ||||
| ASTROTECH CORPORATION AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share and per share data) | ||||||||
| March 31, | June 30, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | (Note) | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 2,679 | $ | 3,100 | ||||
| Short-term investments | 3,903 | 15,108 | ||||||
| Accounts receivable | 504 | 485 | ||||||
| Inventory, net: | ||||||||
| Raw materials | 3,019 | 2,194 | ||||||
| Work-in-process | 531 | 425 | ||||||
| Finished goods | 310 | 310 | ||||||
| Prepaid expenses and other current assets | 383 | 353 | ||||||
| Total current assets | 11,329 | 21,975 | ||||||
| Property and equipment, net | 2,573 | 2,395 | ||||||
| Intangible asset, net | 50 | 48 | ||||||
| Operating lease right-of-use assets, net | 1,906 | 2,225 | ||||||
| Other assets, net | 315 | 346 | ||||||
| Total assets | $ | 16,173 | $ | 26,989 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 234 | $ | 1,066 | ||||
| Payroll related accruals | 461 | 529 | ||||||
| Accrued expenses and other liabilities | 865 | 451 | ||||||
| Lease liabilities, current | 275 | 405 | ||||||
| Total current liabilities | 1,835 | 2,451 | ||||||
| Accrued expenses and other liabilities, net of current portion | 79 | 164 | ||||||
| Lease liabilities, net of current portion | 2,104 | 2,274 | ||||||
| Total liabilities | 4,018 | 4,889 | ||||||
| Commitments and contingencies (Note 14) | ||||||||
| Stockholders’ equity | ||||||||
| Convertible preferred stock, | — | — | ||||||
| Common stock, | 190,643 | 190,643 | ||||||
| Treasury shares, 10,316 at March 31, 2026, and June 30, 2025, respectively | (119 | ) | (119 | ) | ||||
| Additional paid-in capital | 84,050 | 83,310 | ||||||
| Accumulated deficit | (262,030 | ) | (250,870 | ) | ||||
| Accumulated other comprehensive loss | (389 | ) | (864 | ) | ||||
| Total stockholders’ equity | 12,155 | 22,100 | ||||||
| Total liabilities and stockholders’ equity | $ | 16,173 | $ | 26,989 | ||||
Note: The balance sheet at June 30, 2025 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by the United States generally accepted accounting principles for complete financial statements.
